ADIAL PHARMACEUTICALS, INC. (ADIL) Form 8-K — Aug 13, 2026

$ADILForm 8-KItems 5.02, 8.01Filed Aug 13, 2026, 5:25 PM ET0001213900-26-089270Original filing

Adial Pharmaceuticals disclosed on August 13, 2026 that it anticipates terminating President and CEO Cary Claiborne and CFO Vinay Shah promptly after its September 17, 2026 annual meeting, provided stockholders approve certain proposals to be presented at that meeting. Chief Development Officer and director Matthew Davidson is expected to be appointed President and CEO, and a new CFO will be named; both departing executives are entitled to severance payments and benefits under their amended and restated employment agreements upon execution of a release.

Key figures

Annual meeting date: 2026-09-17
Stockholder proposal deadline: 2026-08-23

Price after filing

1 day: -9.3%7 days: +34.4%30 days: +11.6%

Close on the filing date to close N calendar days later (from $4.39). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.